Participants:

Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Brian Flatley VP Consulting Services & US Pharma SolutionsS3 Connected Health
Brian Flatley
VP Consulting Services & US Pharma SolutionsS3 Connected Health
Eugene Borukhovich Co-Founder & COOYourCoach Health
Eugene Borukhovich
Co-Founder & COOYourCoach Health
Evgueni Ivanov Digital Strategy and PortfolioUCB
Evgueni Ivanov
Digital Strategy and PortfolioUCB
Francesca Wuttke Founder & CEOnen Health
Francesca Wuttke
Founder & CEOnen Health
Jochen Hurlebaus President & OwnerXO Life
Jochen Hurlebaus
President & OwnerXO Life
Julie Murchinson PartnerTransformation Capital
Julie Murchinson
PartnerTransformation Capital
Lina Behrens Head of Strategy & Content, Director HTSHLTH Europe
Lina Behrens
Head of Strategy & Content, Director HTSHLTH Europe
Lorcan Walsh Digital Endpoints Capability Centre LeadNovartis
Lorcan Walsh
Digital Endpoints Capability Centre LeadNovartis
Malin Johansson Vice PresidentNovo Nordisk
Malin Johansson
Vice PresidentNovo Nordisk
Matthias Essenpreis CTO Roche DiagnosticsF. Hoffmann-La Roche
Matthias Essenpreis
CTO Roche DiagnosticsF. Hoffmann-La Roche
Murray Brozinsky CEOAmwell
Murray Brozinsky
CEOAmwell
Philip Russmeyer Founder and CEOFitfile
Philip Russmeyer
Founder and CEOFitfile
Ritesh Patel Senior Partner, Global Digital HealthFinn Partners
Ritesh Patel
Senior Partner, Global Digital HealthFinn Partners
Robert Garber Managing Partner7wire Ventures
Robert Garber
Managing Partner7wire Ventures
Steve Seuntjens PartnerPHS Capital
Steve Seuntjens
PartnerPHS Capital
Thorsten Rall Global Industry Lead Life Science, EVPCapgemini
Thorsten Rall
Global Industry Lead Life Science, EVPCapgemini
Tim Ruckh Digital Health Clinical Data Collection LeadAstraZeneca
Tim Ruckh
Digital Health Clinical Data Collection LeadAstraZeneca
William Taranto President, Founder & General PartnerMerck-Global Health Innovation Fund
William Taranto
President, Founder & General PartnerMerck-Global Health Innovation Fund
Amit Sethi KPMG UKPartner
Amit Sethi
KPMG UKPartner
Aoife Ni Mhuiri Founder and CEOSalaso Health Solutions
Aoife Ni Mhuiri
Founder and CEOSalaso Health Solutions
Catherine Wu Product Marketing - Virtual Care SolutionsRoche Hoffman
Catherine Wu
Product Marketing - Virtual Care SolutionsRoche Hoffman
Ciara Clancy Chief Executive OfficerBeats Medical Ltd
Ciara Clancy
Chief Executive OfficerBeats Medical Ltd
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Ernst Bos Global Medical DirectorRoche
Ernst Bos
Global Medical DirectorRoche
Friedrich Lämmel Co-Founder & CEOThryve
Friedrich Lämmel
Co-Founder & CEOThryve
Gabriele Tundo PartnerPlexus Ventures
Gabriele Tundo
PartnerPlexus Ventures
Garret Coady CEOBlueBridge Technologies
Garret Coady
CEOBlueBridge Technologies
Jim O'Donoghue PresidentS3 Connected Health
Jim O'Donoghue
PresidentS3 Connected Health
Jim Joyce DirectorClear IP
Jim Joyce
DirectorClear IP
Keith O'Neill CEONovus Diagnostics
Keith O'Neill
CEONovus Diagnostics
Kerry Naughton Marketing DirectorBluebridge Technologies
Kerry Naughton
Marketing DirectorBluebridge Technologies
Kevin Darcy Director, Link StrategyVeeva
Kevin Darcy
Director, Link StrategyVeeva
Laura Nelde Senior ConsultantFlying Health
Laura Nelde
Senior ConsultantFlying Health
Marie Mc Carthy DEVELOP. UNIT DIGITAL ENDPOINT LEADNovartis
Marie Mc Carthy
DEVELOP. UNIT DIGITAL ENDPOINT LEADNovartis
Marius Mainz Senior Business Development ManagerHelloBetter
Marius Mainz
Senior Business Development ManagerHelloBetter
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Nicole Baker CEObiologit
Nicole Baker
CEObiologit
Ryan Sysko CEOAmalgamRx
Ryan Sysko
CEOAmalgamRx
Stephen Egan DirectorRedicare
Stephen Egan
DirectorRedicare
Tim Juergens PartnerCrossroad Biotech
Tim Juergens
PartnerCrossroad Biotech

About this Meeting

Precision Digital Therapeutics - the right DTx at the right time, for the right patient.

Places are extremely limited for both our Boston and Dublin events and are exclusively available to HealthXL members only. These events will not be streamed, recorded or shared - rather they are special member only events. Our events are collaborative in nature - there will be no keynote speakers, but rather a coming together of like-minded people to discuss & innovate the future of digital health.

HealthXL events comply with local and international recommendations and require all attendees to be fully vaccinated against Covid-19, and be able to provide proof of the same when required.


Agenda for the Event

We will explore precision digital therapeutics over two 90-minute sessions (Morning and Afternoon) with a break in-between for a networking lunch. In order to facilitate collaboration and shared insights with your peers, our event will be roundtable based (8 per table) with each table being afforded the opportunity to present their findings.

Morning Session - Selecting the Right DTx for a Patient (11:00am - 12:30pm)

Patients with a given condition are heterogenous where some drugs work better for different patients over others. The same will hold true for DTx solutions within a given condition. Understanding what DTx will work in a particular group of patients and how to make those decisions efficiently will be critical for DTx success in a broader population. What do we need to do now to realise this?

  • What data is required to differentiate between DTx solutions in a given condition and how should evidence be generated?
  • How can we modulate DTx dosing to suit different patient cohorts
  • What should CDSS look like for DTx solutions


Afternoon Session - How should Pharma and DTx developers collaborate to create a DTx ecosystem for different therapy areas? (1:30pm - 3:00pm)

Choosing the best combination of drug and DTx for a given patient will by its nature require brand-agnostic DTx solutions and the ability for patients to either change drugs and retain their DTx or vice versa. While this will involve many more stakeholders than just pharma and DTx developers, we want to start the discussion with this group.

  • How should DTx developer and pharma partnerships change to allow for brand-agnostic companion DTx solutions?
  • Who will invest in the required infrastructure to realise a condition-wide DTx ecosystem? What is the role for Pharma and what return would they expect?
  • How do we build a coalition of key stakeholders to create a condition-wide DTx ecosystem?